GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Patient Information Leaflet last updated on the eMC: 14/11/2011
PIL ReQuip XL prolonged-release tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 14/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to how the medicine works
  • Change to date of revision
Updated on 11/04/2011 and displayed until 14/11/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 08/11/2010 and displayed until 11/04/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to manufacturer contact details
Updated on 18/11/2008 and displayed until 08/11/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
Updated on 28/05/2008 and displayed until 18/11/2008
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   ropinirole hydrochloride